Janssen Gains FDA Accelerated Approval for Rybrevant Faspro

Subcutaneous delivery of a bispecific antibody has cleared a significant regulatory threshold: Janssen Biotech received FDA accelerated approval on November 5, 2026, for amivantamab and hyaluronidase-lpuj (Rybrevant Faspro) in adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease progressed on or after platinum-based chemotherapy and an anti-PD-(L)1 antibody. For CMC and regulatory teams, the approval signals that subcutaneous formulation strategies paired with concurrent international review are now a viable path for oncology biologics.

Efficacy data supporting the approval came from the OrigAMI-4 trial (NCT06385080), a multicenter, open-label, multi-cohort study enrolling 102 patients in the primary efficacy population. Blinded independent central review per RECIST v1.1 returned an overall response rate of 42% (95% CI: 32%, 52%), with 56% of responders sustaining a duration of response of six months or longer. The indication explicitly excludes patients with HPV-associated oropharyngeal squamous cell carcinoma, confirmed by p16 testing, a population-definition detail that QA and medical affairs teams should encode precisely into labeling controls and promotional review processes.

The prescribing information carries warnings and precautions for hypersensitivity and administration-related reactions, interstitial lung disease/pneumonitis, dermatologic adverse reactions, ocular toxicity, and embryo-fetal toxicity. Dosing is weight-based and administered subcutaneously every three weeks, a schedule that has direct implications for site-of-care logistics, cold-chain management, and pharmacovigilance infrastructure at the dispensing level.

The review was conducted under Project Orbis, the FDA Oncology Center of Excellence initiative enabling concurrent submission and review across international partners. Collaborating agencies for this application included Brazil's ANVISA, Health Canada, Israel's Ministry of Health, and Singapore's Health Sciences Agency, though those reviews remain ongoing. For regulatory affairs leads, the multi-agency submission architecture here illustrates how Project Orbis can compress global approval timelines when CMC packages are structured for simultaneous dossier requirements across jurisdictions. Janssen also submitted an Assessment Aid, a voluntary tool that can streamline FDA's internal review workflow and is worth factoring into submission strategy for complex biologics.

The application carried both priority review designation and breakthrough therapy designation, reflecting the unmet need in a platinum- and checkpoint inhibitor-refractory population where approved options remain limited.

Full prescribing information will be posted to Drugs@FDA, and the ongoing confirmatory trial data required under accelerated approval will set the next measurable checkpoint for this program's continued market status.

Source: FDA Drugs Resources and Information, Approved Drugs (What's New: Drugs RSS Feed) via fda.gov, November 5, 2026.